ACAD ACADIA Pharmaceuticals Inc.

36.55
-0.43  -1%
Previous Close 36.98
Open 37.17
Price To book 10.78
Market Cap 4473731184
Shares 122,400,306
Volume 836,769
Short Ratio 10.79
Av. Daily Volume 1,450,052

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171080802
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015184
  3. S-8 - Securities to be offered to employees in employee benefit plans 171015136
  4. 8-K - Current report 171014956
  5. 8-K - Current report 17913634

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated November 2016.
Pimavanserin
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 initiated November 2016.
Pimavanserin
Adjunctive treatment of schizophrenia
Phase 2 trial initiated October 2016.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016
Pimavanserin
Parkinson’s disease psychosis (PDP)
Phase 2 top-line data released December 20, 2016. Primary endpoint met. Key secondary endpoint missed. Phase 3 trial to be initiated 2H 2017.
Pimavanserin
Alzheimer’s disease psychosis